Westchester Capital Management Inc. lowered its stake in Becton Dickinson and Co (NYSE:BDX) by 0.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,406 shares of the medical instruments supplier’s stock after selling 260 shares during the period. Becton Dickinson and accounts for 4.1% of Westchester Capital Management Inc.’s holdings, making the stock its 11th largest holding. Westchester Capital Management Inc.’s holdings in Becton Dickinson and were worth $10,285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently modified their holdings of the business. Acropolis Investment Management LLC acquired a new position in shares of Becton Dickinson and during the third quarter worth $101,000. Almanack Investment Partners LLC. bought a new position in Becton Dickinson and during the second quarter worth $105,000. Truvestments Capital LLC bought a new position in Becton Dickinson and during the third quarter worth $105,000. Bartlett & Co. LLC raised its stake in Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 435 shares during the last quarter. Finally, Bridgeworth LLC bought a new position in Becton Dickinson and during the second quarter worth $131,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
In other Becton Dickinson and news, EVP James C. Lim sold 5,189 shares of Becton Dickinson and stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the sale, the executive vice president now directly owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting the consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The firm had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the previous year, the firm posted $2.40 earnings per share. The business’s revenue was up 39.0% compared to the same quarter last year. On average, equities analysts predict that Becton Dickinson and Co will post 12.2 earnings per share for the current year.
BDX has been the subject of a number of analyst reports. KeyCorp reissued a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research note on Friday, August 3rd. Royal Bank of Canada reissued a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a research note on Friday, August 3rd. Citigroup lifted their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Wells Fargo & Co lifted their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Finally, Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $254.07.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (BDX) Shares Sold by Westchester Capital Management Inc.” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://sportsperspectives.com/2018/11/10/becton-dickinson-and-co-bdx-shares-sold-by-westchester-capital-management-inc.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Stock Symbol
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.